APA

Hümmert M. W., Deppe J., Pul R., Wurster U., Schwenkenbecher P., Sühs K., Bronzlik P., Stangel M. & Skripuletz T. (20181011). Severe CNS inflammation after discontinuation of natalizumab and start of daclizumab successfully treated with alemtuzumab. : Multiple sclerosis and related disorders.

Chicago

Hümmert Martin W, Deppe Julian, Pul Refik, Wurster Ulrich, Schwenkenbecher Philipp, Sühs Kurt-Wolfram, Bronzlik Paul, Stangel Martin and Skripuletz Thomas. 20181011. Severe CNS inflammation after discontinuation of natalizumab and start of daclizumab successfully treated with alemtuzumab. : Multiple sclerosis and related disorders.

Harvard

Hümmert M. W., Deppe J., Pul R., Wurster U., Schwenkenbecher P., Sühs K., Bronzlik P., Stangel M. and Skripuletz T. (20181011). Severe CNS inflammation after discontinuation of natalizumab and start of daclizumab successfully treated with alemtuzumab. : Multiple sclerosis and related disorders.

MLA

Hümmert Martin W, Deppe Julian, Pul Refik, Wurster Ulrich, Schwenkenbecher Philipp, Sühs Kurt-Wolfram, Bronzlik Paul, Stangel Martin and Skripuletz Thomas. Severe CNS inflammation after discontinuation of natalizumab and start of daclizumab successfully treated with alemtuzumab. : Multiple sclerosis and related disorders. 20181011.